Contract Pharma Manufacturing News

  1. Celularity Reiterates Strategic Commercialization Partnership With NEXGEL Focused On Building Biomaterials Franchise With Established Commercial Products and New 510(k) Pathway Product Opportunities 3/12/2026

    Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company focused on longevity science, today reiterated that its strategic commercialization partnership with NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL) is a focused effort by the two companies to rapidly capitalize on renewed regulatory and reimbursement clarity around placental-derived biomaterials and build sales and market share. The transaction is expected to close no later than April 15, 2026, subject to customary closing conditions.

  2. Earendil Labs And WuXi Biologics Enter Strategic Collaboration To Accelerate Development And Manufacturing Of Bispecific/Multispecific Antibodies And ADCs 3/12/2026

    Earendil Labs, a global leader in AI-driven research and development of next-generation biologics therapeutics, and WuXi Biologics (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), today jointly announced the signing of a strategic collaboration agreement on the development and manufacturing of multiple novel bispecific and multispecific antibodies and ADC candidates in Earendil Labs' pipeline targeting autoimmune disease, cancer, and other diseases.

  3. Trenchant BioSystems And Invetech Group Complete Strategic Alliance Formation To Develop Fully Automated CGT Manufacturing Solution 3/12/2026

    Trenchant BioSystems Inc., the CGT manufacturing platform developer for gene-modified cells, and Invetech, a global leader in solving complex manufacturing and product development challenges in the advanced therapies and diagnostics markets, announce that they have entered into a strategic alliance, The alliance will collaborate on the continued development of Trenchant’s fully automated AutoCell Platform, intended for future commercialization.

  4. Fujifilm Invests In VALANX Biotech To Strengthen ADC CDMO Capabilities 3/12/2026

    FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announces its investment in VALANX Biotech (Vienna, Austria; hereinafter “VALANX”), an Austrian biotechnology company with advanced manufacturing technologies for antibody-drug conjugates (ADCs), one of the key next-generation biopharmaceutical modalities.

  5. Merck Signs MoU With Cyto-Facto To Advance Cell And Gene Therapy Development And Manufacturing In APAC 3/11/2026

    Merck, a leading science and technology company, has signed a non-binding Memorandum of Understanding (MoU) with Cyto-Facto Inc., a specialist CDMO (Contract Development and Manufacturing Organization) focused on cell and gene therapies.

  6. George Medicines Signs Exclusive Licensing Agreement With Ahngook Pharmaceutical To Commercialize GMRx2 In Korea 3/11/2026

    George Medicines, a late-stage biopharmaceutical company focused on addressing significant unmet needs in cardiometabolic disease, has entered into an exclusive licensing and supply agreement with Ahngook Pharmaceutical Co. Ltd (“Ahngook Pharm”) (KOSDAQ: 001540), of Seoul, Korea, granting Ahngook Pharm exclusive rights to seek regulatory approval of, and to commercialize, GMRx2 in Korea.

  7. Bavarian Nordic And Serum Institute Of India Expand Strategic Partnership With Chikungunya Vaccine Manufacturing Agreement 3/11/2026

    Copenhagen, Denmark Bavarian Nordic A/S (OMX: BAVA) today announced an expansion of the strategic partnership with Serum Institute of India Pvt. Ltd. (SII) to include a contract manufacturing agreement covering a full tech transfer of the manufacturing process for the chikungunya vaccine (CHIKV VLP) from Bavarian Nordic to SII to allow for scaling of capacity to enable future supply to endemic low- and middle-income countries (LMICs).

  8. Samsung Biologics Announces Collaboration With Lilly To Establish New Gateway Labs Site In Korea 3/10/2026

    Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), announced a collaboration agreement with Eli Lilly and Company (Lilly) to establish a Lilly Gateway Labs (LGL) site in Korea.

  9. mAbxience Selects Genedata Bioprocess To Automate End-To-End CDMO Workflows 3/10/2026

    Genedata, a Danaher company and the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that mAbxience has selected the Genedata Bioprocess® enterprise platform to structure and harmonize all bioprocess development data across its operations.

  10. Polyrizon Announces GMP Manufacturing Of Clinical Trial Material (CTM) With Eurofins CDMO AmatsiAquitaine S.A.S For Planned U.S. Clinical Study 3/10/2026

    Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal administrated solutions, today announced the successful production of a Good Manufacturing Practice (GMP) batch of clinical trial material (CTM) for its lead product candidate.